Dear Editor,
The mechanistic pathways leading to immune dysregulation and complications driven by uncontrolled severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) infection remain major challenges. 1 , 2 Hence, a detailed analysis of the proteome, metabolome and lipidome profile of coronavirus disease 2019 (COVID‐19) patients showing different severity grades might shed light on the disease pathophysiology and unveil new predictive biomarkers to promptly ascertain patient's outcomes.
Our COVID‐19 study cohort included 273 SARS‐CoV‐2 infected individuals recruited during the first wave (March–April 2020) in three different hospitals and grouped by the disease severity following the medical inclusion criteria 3 in mild, severe or critical (Figure 1A), from whom demographic, preexisting clinical conditions and COVID‐19 treatments are summarized in Table S1. The greatest significant differences were observed between mild and critically ill patients. These findings indicated that older individuals with comorbidities such as hypertension, obesity, diabetes and cardiovascular disorders, mostly presenting dyspnea (Figure 1B), may be at higher risk of suffering from severe respiratory distress with subsequent oxygen and drug requirements and, eventually, died. Similarly, the serum biochemical composition analysis revealed a well‐differentiated blood pattern previously defined for critically ill patients (Figure S1).
In light of the promising results already provided by omic technologies in the search for predictive biomarkers of COVID‐19 severity, 4 , 5 we conducted a nontargeted multi‐omic, including proteomic, metabolomic and lipidomic analyses, in the serum from patients of the COVID‐19 study cohort. The proteomics analysis identified 65 proteins with a significant increase or decrease in abundance according to the disease severity (Figure 2A), which resulted to be highly interconnected (Figure 2B). Hence, the complement and coagulation cascades were markedly the most significantly enriched pathways related to COVID‐19 severity (Figure 2C). Other protein‐coding genes such as carboxypeptidases, protease inhibitors, acute phase proteins, extracellular matrix stabilizers and antimicrobial enzymes, were also significantly up‐regulated in severely and critically ill patients. These results showed the essential contribution of these proteins in the coagulopathy phenomenon and hyperinflammatory state that subsequently enhances SARS‐CoV‐2 endocytosis and infectivity and promotes secondary bacterial infections, previously described as aggravators of severe and critical COVID‐19 cases. 6 Proteins with reduced abundance in critically ill patients with COVID‐19 were mostly associated with lipid transport (apolipoproteins), which dysfunction seems to increase SARS‐CoV‐2 infectivity in patients with COVID‐19. 7 For the first time, fetuin‐A (AHSG) and inter‐α‐trypsin inhibitor 3 (ITIH3) were determined as the most accurate biomarkers (random forest) of the critical clinical progression of COVID‐19 (Figure 2D).
The metabolomic and lipidomic analyses revealed 34 metabolites and 28 lipids that were significantly increased or decreased in relation to severity (Figure 3A). Interestingly, many of the altered metabolites were amino acids and sugars involved in central carbon metabolism. In line with previous reports, 8 , 9 critically ill patients showed a significant increase in glucose and glutamic acid (GA) levels but a reduction in glutamine, citrate and uric acid levels, suggesting mitochondrial dysfunction, an enhanced glutaminolysis and a shift from anaerobic to aerobic glycolysis (Warburg effect). Accordingly, D‐glutamine and D‐glutamate metabolism were the most significantly enriched pathways (Figure 3B, left panel), and were significantly related to seizures disorders, anoxia, heart failure, diabetes, obesity and inflammatory diseases (Figure 3B, right panel). Lipid levels that increased with severity were mainly triglycerides (TGs) and diacylglycerols, and those that decreased were predominantly sphingomyelins (SMs), cholesteryl esters (ChoEs) and lysophosphatidylcholines. Lipoproteins rich in TGs may trigger dysfunction in innate immunity and impair the defence mechanism against COVID‐19 10 and a reduced abundance of SMs and ChoEs may interfere in signal transduction and in key immune and cellular processes. Among them, GA and ChoE (18:0) resulted in the most powerful (random forest) predictive biomarkers for COVID‐19 evolution (Figure 3C), confirmed by the prognosis accuracy determined by the receiver operating characteristic (ROC) analysis (Figure S2A–C, respectively). The highest accuracy was attained when combining both compounds in the distinction of mild from critical illnesses (Figure 2SD). To provide insights into the biological pathways related to the pathophysiology of the disease, we study the linkage and co‐regulation between the distinct classes of biomolecules by integrating the most significant demographical and clinical data (Table S1 and Figure S1) and the top omic molecules determined above (Figure S3A,B) in Spearman correlation matrix analyses (Figure 4A1–3). Despite all three groups showing a similar association pattern for most of the variables analyzed, patients with mild illness (Figure 4A1) significantly differed from those of the severe and critical groups (Figure 4A2,3, respectively). In brief, significant correlations were obtained across the omic data, which were more intense between lipidomics than within the protein‐encoding genes, and nearly negligible through metabolomics. The predictive power of the selected omics biomolecules as biomarkers for the severe disease was subsequently demonstrated by the high accuracy, sensitivity and specificity obtained by combining the four molecules in the ROC analysis (Figure 4B) to effectively distinguish critical COVID‐19 patients from patients with mild disease (area under the curve [AUC] = 0.994). To precisely predict whether a patient will progress from severe to a life‐threatening disease, not only the four but all the top‐omic selected biomarkers need to be integrated into the ROC analysis (AUC = 0.811; Figure 4C).
Taking a step further, the inclusion of AHSG, ITIH, GA and ChoE (18:0) in a predictive biomarker panel for COVID‐19 severity was validated in a randomly selected subset of patients. The regression modelling analysis confirmed the usefulness (classification accuracy >90%) of the biomarker panel in distinguishing mild to critical COVID‐19 outcomes (Figure 4D). Once more, all these findings highlighted the complex interactions between certain biological processes and the most serious complications arising from SARS‐CoV‐2 infections and revealed their potential as predictive biomarkers of disease severity.
Limitations are the small sample size to perform subgroup analyses and the lack of a non‐infected SARS‐CoV‐2 group of subjects. However, this study was conducted in a representative symptomatic well‐characterized Spanish cohort to determine predictive biomarkers of COVID‐19 severity.
In conclusion, the multi‐omic analysis identified new specific molecules related to complement and coagulation cascades, platelet activation, cell adhesion, acute inflammation, energy production (Krebs cycle and Warburg effect), amino acid catabolism and lipid transport as fingerprints of the acute disease. A novel biomarker panel consisting of AHSG, ITIH3, GA and ChoE (18:0) was proposed for the accurate differentiation of mild from critical COVID‐19 outcomes.
FUNDING INFORMATION
This work has been developed in the framework of the COVIDOMICS’ project supported by Direcció General de Recerca i Innovació en Salut (DGRIS), Departament de Salut, Generalitat de Catalunya (PoC‐6‐17 and PoC1‐5). The research has also been funded by the Programa de Suport als Grups de Recerca AGAUR (2017SGR948), the SPANISH AIDS Research Network [RD16/0025/0006, RD16/0025/0007 and RD16/0025/0020]‐ISCIII‐FEDER (Spain), the Centro de Investigación Biomédica en Red de Enfermedades Infecciosas‐ISCIII [CB21/13/00020], Madrid, Spain and Consejeria de Transformacion Economica, Industria, Conocimiento y Universidades Junta de Andalucía (research Project CV20‐85418). Elena Yeregui was supported by the Instituto de Salud Carlos III (ISCIII) under grant agreement “FI20/00118″ through the programme “Contratos Predoctorales de Formación en Investigación en Salud”. Laia Reverté was supported by the Instituto de Salud Carlos III (ISCIII) under grant agreement “CD20/00105″ through the programme “Contratos Sara Borrell”. Francesc Vidal was supported by grants from the Programa de Intensificación de Investigadores (INT20/00031)‐ISCIII and by “Premi a la Trajectòria Investigadora dels Hospitals de l'ICS 2018″. Anna Rull was supported by a grant from IISPV through the project “2019/IISPV/05″ (Boosting Young Talent), by GeSIDA through the “III Premio para Jóvenes Investigadores 2019″ and by the Instituto de Salud Carlos III (ISCIII) under grant agreement “CP19/00146″ through the Miguel Servet Program. Maria José Buzón was supported by the Miguel Servet Program (CP17/00179). Ezequiel Ruiz‐Mateos was supported by the Spanish Research Council (CSIC). Alicia Gutiérrez‐Valencia was supported by the Instituto de Salud Carlos III, cofinanced by the European Development Regional Fund (“A way to achieve Europe”), Subprograma Miguel Servet (grant CP19/00159). This project was also funded by a donation from the city Council of Perafort (to Teresa Auguet).
CONFLICT OF INTEREST
The authors declare that they have no conflict of interest.
Supporting information
ACKNOWLEDGEMENTS
This study would not have been possible without the generous collaboration of all the patients and their families and medical and nursing staff who have taken part in the project. We want to particularly acknowledge the collaboration of the Departments of Preventive Medicine and Epidemiology, Internal Medicine, Critical Care, Emergency, Occupational Health, Laboratory Medicine and Molecular Biology, and BioBank‐IISPV (B.0000853 and B.0000854) integrated into the Spanish National Biobanks Platform (PT20/00197) and CERCA Programme (Generalitat de Catalunya) and IISPV for their collaboration. We also thank Pol Herrero, Maria Guirro and Antoni del Pino from the Proteomics and Metabolomics facilities of the Centre for Omic Sciences (COS) Joint Unit of the Universitat Rovira i Virgili‐Eurecat for their contribution to mass spectrometry analyses.
Contributor Information
Francesc Vidal, Email: fvidalmarsal.hj23.ics@gencat.cat.
Anna Rull, Email: anna.rull@iispv.cat.
REFERENCES
- 1. WHO . COVID‐19 therapeutic trial synopsis. World Health Organization. 2020;1‐9
- 2. Domingo P, Mur I, Pomar V, et al. The four horsemen of a viral apocalypse: the pathogenesis of SARS‐CoV‐2 infection (COVID‐19). EBioMedicine. 2020;58:102887. 10.1016/J.EBIOM.2020.102887. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Wang GQ, Zhao L, Wang X, Jiao YM, Wang FS. Diagnosis and treatment protocol for COVID‐19 patients (tentative 8th edition). Infect Dis Immun. 2021;1:8‐16. 10.1097/01.id9.0000733564.21786.b0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Wang X, Xu G, Liu X, et al. Multiomics: unraveling the panoramic landscapes of SARS‐CoV‐2 infection. Cell Mol Immunol. 2021;18:2313‐2324. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. McArdle A, Washington KE, Chazarin Orgel B, et al. Discovery proteomicsfor COVID‐19: where we are now. J Proteome Res. 2021;20:4627. 10.1021/ACS.JPROTEOME.1C00475. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID‐19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054‐1062. 10.1016/S0140-6736(20)30566-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Wang H, Yuan Z, Pavel MA, et al. The role of high cholesterol in age‐related COVID19 lethality. BioRxiv. 2020. 10.1101/2020.05.09.086249. [DOI] [Google Scholar]
- 8. Wu D, Shu T, Yang X, et al. Plasma metabolomic and lipidomic alterations associated with COVID‐19. Nat Sci Rev. 2020;7:1157‐1168. 10.1093/NSR/NWAA086. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Bharadwaj S, Singh M, Kirtipal N, Kang SG. SARS‐CoV‐2 and Glutamine: SARS‐CoV‐2 triggered pathogenesis via metabolic reprograming of glutamine in host cells. Front Mol Biosci. 2021;7. 10.3389/fmolb.2020.627842. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. McKechnie JL, Blish CA. The innate immune system: fighting on the front lines or fanning the flames of COVID‐19? Cell Host Microbe. 2020;27:863‐869. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.